ClinVar Miner

Submissions for variant NM_004360.5(CDH1):c.2413G>A (p.Asp805Asn)

gnomAD frequency: 0.00016  dbSNP: rs200894246
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 19
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen CDH1 Variant Curation Expert Panel RCV000123247 SCV000864617 benign Hereditary diffuse gastric adenocarcinoma 2018-11-21 reviewed by expert panel curation The c.2413G>A (p.Asp805Asn) variant has an allele frequency of 0.00207 (0.21%, 21/10,148 alleles) in the Ashkenazi Jewish subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: BA1.
GeneDx RCV000858568 SCV000149763 likely benign not provided 2021-03-03 criteria provided, single submitter clinical testing This variant is associated with the following publications: (PMID: 29348693, 25980754, 25862857, 24728327, 25637381, 26601054, 26845104, 26580448, 26182300, 23197654, 28135145, 28873162, 28767289)
Invitae RCV000123247 SCV000166553 benign Hereditary diffuse gastric adenocarcinoma 2021-12-17 criteria provided, single submitter clinical testing
Ambry Genetics RCV000115854 SCV000186424 benign Hereditary cancer-predisposing syndrome 2019-01-17 criteria provided, single submitter clinical testing General population or subpopulation frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance;Other data supporting benign classification;Other strong data supporting benign classification
University of Washington Department of Laboratory Medicine,University of Washington RCV000115854 SCV000266163 uncertain significance Hereditary cancer-predisposing syndrome 2015-11-20 criteria provided, single submitter clinical testing
Color Health, Inc RCV000115854 SCV000684433 likely benign Hereditary cancer-predisposing syndrome 2017-12-06 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000120505 SCV000917126 benign not specified 2021-11-08 criteria provided, single submitter clinical testing Variant summary: CDH1 c.2413G>A (p.Asp805Asn) results in a conservative amino acid change located in the Cadherin, cytoplasmic domain (IPR000233) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00024 in 251938 control chromosomes. The observed variant frequency is approximately 9 fold of the estimated maximal expected allele frequency for a pathogenic variant in CDH1 causing Hereditary Diffuse Gastric Cancer phenotype (2.8e-05), strongly suggesting that the variant is benign. c.2413G>A has been reported in the literature in a family with gastric and diffuse gastric cancer in an unaffected patient; however the age was not provided (Hansford_2015). An additional CDH1 variant (c.2430delT) was also identified in a proband affected with DGC in this family. This variant was also observed associated with non-syndromic cleft-palate, Lynch Syndrome, pancreatic ductal adenocarcinoma, and NSCLC patients without strong evidence for causality (Vogelaar_2013, Yurgelun_2015, Yurgelun_2017, Rangachari_2015, Shindo_2017, Shirts_2016). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Diffuse Gastric Cancer. At-least one co-occurrence with another pathogenic variant has been observed at our laboratory (BRCA2 c.7618-1G>A), providing supporting evidence for a benign role. At least one publication reports experimental evidence evaluating an impact on protein function (Vogelaar_2013). The most pronounced variant effect results in slightly impaired cell invasion suppression, displaying smaller cellular aggregates than the WT and to result in reduced membranous E-cadherin expression while not affecting the expression level of CDH1. However, the clinical relevance of these functional impacts is uncertain. Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments with a majority consensus leaning towards benign/likely benign (n=8). Based on the evidence outlined above, the variant was classified as benign.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000858568 SCV001134079 likely benign not provided 2020-03-06 criteria provided, single submitter clinical testing
Mendelics RCV000123247 SCV001140153 uncertain significance Hereditary diffuse gastric adenocarcinoma 2019-05-28 criteria provided, single submitter clinical testing
Illumina Laboratory Services,Illumina RCV000123247 SCV001274533 likely benign Hereditary diffuse gastric adenocarcinoma 2017-04-28 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign.
St. Jude Clinical Genomics Lab, St. Jude Children's Research Hospital RCV000123247 SCV001439187 benign Hereditary diffuse gastric adenocarcinoma 2020-09-09 criteria provided, single submitter clinical testing
CHEO Genetics Diagnostic Laboratory,Children's Hospital of Eastern Ontario RCV001798346 SCV002043271 likely benign Breast and/or ovarian cancer 2021-05-03 criteria provided, single submitter clinical testing
Sema4,Sema4 RCV000115854 SCV002529133 likely benign Hereditary cancer-predisposing syndrome 2020-10-01 criteria provided, single submitter curation
ITMI RCV000120505 SCV000084658 not provided not specified 2013-09-19 no assertion provided reference population
CSER _CC_NCGL, University of Washington RCV000123247 SCV000190153 uncertain significance Hereditary diffuse gastric adenocarcinoma 2016-08-15 no assertion criteria provided research Originally interpreted based on literature review PMID: 25637381. Found in a female patient having exome sequencing for an unrelated indication. No known history of diffuse gastric cancer or breast cancer.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001357821 SCV001553408 likely benign Malignant tumor of breast no assertion criteria provided clinical testing The CDH1 p.Asp805Asn variant was identified in 2 of 2886 proband chromosomes (frequency: 0.0007) from individuals or families with hereditary diffuse gastric cancer or Lynch syndrome and was present in 1 of 1362 control chromosomes (frequency: 0.0007) from healthy individuals (Bodian 2014, Hansford 2015, Yurgelun 2015). The variant was also identified in dbSNP (ID: rs200894246) as "With other allele", ClinVar (classified as benign by Invitae; as likely benign by GeneDx and Ambry Genetics; as uncertain significance by four submitters). The variant was identified in control databases in 63 of 276968 chromosomes at a frequency of 0.0002 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 2 of 6460 chromosomes (freq: 0.0003), Latino in 13 of 34404 chromosomes (freq: 0.0004), European in 26 of 126584 chromosomes (freq: 0.0002), Ashkenazi Jewish in 21 of 10148 chromosomes (freq: 0.002), and South Asian in 1 of 30770 chromosomes (freq: 0.00003), while the variant was not observed in the African, East Asian, and Finnish, populations. One study performed in vitro functional assay (Vogelaar 2013) and found that the variant p.Asp805Asn affects E-cadherin protein function and its subcellular localization and can be considered as a pathogenic mutation however result have no additional functional work supports this claim and more over this missense variant and similar ones in this study have been found in families without a clinical phenotype suggesting that the in vitro data does not reflect the clinical impact of the variants. The p.Asp805 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.
Genome Diagnostics Laboratory, Amsterdam University Medical Center RCV000120505 SCV001807465 benign not specified no assertion criteria provided clinical testing
Clinical Genetics, Academic Medical Center RCV000858568 SCV001919798 likely benign not provided no assertion criteria provided clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital RCV000120505 SCV002551796 benign not specified 2022-05-31 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.